News

January 13, 2026 in Company News, Homepage News, News Highlight, RAG-17, Uncategorized

Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

Nantong, China – January 13, 2026 – Ractigen Therapeutics is pleased to announce that the…
Read More
December 12, 2025 in Homepage News, News Highlight

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

NANTONG, China, December 12, 2025 – Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA)…
Read More
November 17, 2025 in Homepage News, News Highlight

Ractigen Publishes Foundational Paper Detailing Its SCAD Platform for Duplex RNA Delivery to the CNS and Beyond in Molecular Therapy – Nucleic Acids

SUZHOU, China, November 17, 2025 – Ractigen Therapeutics, a clinical-stage biotechnology company, today announced the publication…
Read More
April 9, 2025 in Homepage News, News Highlight, RAG-17

Ractigen’s RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances

Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant…
Read More